IntermediateSITUATIONAL
You discover midway through execution that a pivotal real-world evidence initiative supporting an oncology asset is delayed; what immediate actions do you take to mitigate commercial impact and keep launch timelines credible to internal and external stakeholders?
Oncology Marketing for Industrial Placement at Pfizer
General

Sample Answer

When a delayed RWE study hit our timeline in a prior role, I immediately convened a cross-functional war room with clinical, HEOR, regulatory, commercial and the external vendor. We re-prioritized deliverables: pulled forward interim analyses and generated rapid, high-quality audit-ready snapshots from existing registry data. I re-phased the external communications plan—shared an adjusted evidence timeline with three concrete milestones and contingency data sources—so KOLs and payers saw progress. Internally I reallocated 15% of budget to accelerate analytics and added two contract analysts, cutting expected delay from 6 months to 8 weeks for the first interim. We retained launch credibility by aligning field messaging to clinical endpoints already proven and by offering a clear plan for when the RWE will supplement coverage discussions.

Keywords

Create cross-functional war room and reprioritize deliverablesProduce interim analyses and leverage alternative data to bridge gapsTransparent stakeholder communication with concrete milestonesShorten delay by reallocating resources and setting contingency plans